Marimed (MRMD) Cash & Equivalents (2011 - 2026)

Marimed (MRMD) has 16 years of Cash & Equivalents data on file, last reported at $7.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.9 million, up 10.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 million (up 10.22% YoY), and the FY2025 annual result was $8.9 million, up 22.0% from the prior year.
• Cash & Equivalents eased to $7.9 million in Q1 2026 per MRMD's latest filing, from $8.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $33.5 million in Q1 2022 and troughed at $6.1 million in Q2 2025.
• A 5-year average of $12.1 million and a median of $9.8 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 171.68% in 2022 and fell as far as 67.2% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $9.7 million in 2022, then soared by 50.41% to $14.6 million in 2023, then sank by 50.28% to $7.3 million in 2024, then increased by 22.0% to $8.9 million in 2025, then dropped by 10.66% to $7.9 million in 2026.
• Business Quant data shows MRMD's Cash & Equivalents at $7.9 million in Q1 2026, $8.9 million in Q4 2025, and $6.6 million in Q3 2025.